Stem cell transplantation for chronic myeloid leukemia in children.

Hematopoietic stem cell transplantation (SCT) is the only proven cure for chronic myeloid leukemia (CML), a rare disease in childhood. We report outcomes of 314 children with Philadelphia-chromosome-positive (Ph+) CML undergoing SCT from HLA-matched siblings (n = 182) or volunteer-unrelated donors (VUD; n = 132). Three-year overall survival (OS) and leukemia-free survival (LFS) rates were 66% and 55% (n = 314). For 156 children in first chronic phase (CP1) who underwent transplantation from HLA-identical siblings, OS and LFS rates were 75% and 63%. For 97 children who underwent SCT in CP1 from VUD, 3-year OS and LFS rates were 65% and 56%, reflecting higher transplantation-related mortality (TRM) after VUD SCT (35% vs 20%; multivariate hazard ratio [HR], 1.9; 95% confidence interval [CI], 1.0-3.5; P =.05). In a multivariate model for OS and LFS, outcomes were superior in CP1 than in advanced phase (AP/CP1) (OS HR, 2.0; 95% CI, 1.3-3; P =.001; LFS HR, 1.8; 95% CI, 1.2-2.6; P =.003). For relapse, donor source (VUD/sibling) (HR, 0.38; 95% CI, 0.19-0.76; P =.006) and disease stage (AP/CP1) (HR, 2.4; 95% CI, 1.36-4.3; P =.003) were significant. This is the first large series to show that SCT confers long-term LFS in most children with CML and helps assess alternative therapy, including tyrosine kinase inhibitors.

[1]  C. Craddock,et al.  Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. , 2002, Blood.

[2]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[3]  J. Wagner,et al.  Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. , 2001, The American journal of medicine.

[4]  C. Craddock,et al.  Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis , 2001, British journal of haematology.

[5]  C. Craddock,et al.  Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia , 2000 .

[6]  V. Kuenen-Boumeester,et al.  Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.

[7]  A. Nademanee,et al.  Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. , 2000, Blood.

[8]  J. Klein,et al.  Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. , 2000, Blood.

[9]  W. Siegert,et al.  Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure , 1999 .

[10]  S. Woolf,et al.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.

[11]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[12]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[13]  K. Sullivan,et al.  Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase , 1998 .

[14]  Lamparelli,et al.  Unrelated donor marrow transplantation for chronic myelogenous leukaemia , 1998, British journal of haematology.

[15]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[16]  H. Heimpel,et al.  Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. , 1998, Blood.

[17]  G. Gahrton,et al.  Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 1997, Bone Marrow Transplantation.

[18]  D. Srivastava,et al.  Outcomes of transplantation with matched-sibling and unrelateddonor bone marrow in children with leukaemia , 1997, The Lancet.

[19]  M. Labopin,et al.  European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching , 1997, Bone Marrow Transplantation.

[20]  J. Klein,et al.  IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.

[21]  A. Gratwohl,et al.  Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 1997, Bone Marrow Transplantation.

[22]  J P Klein,et al.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Locatelli,et al.  Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: experience of eight European Countries. The EBMT Paediatric Diseases Working Party. , 1996, Bone marrow transplantation.

[24]  G. Hale,et al.  Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission , 1996, British journal of haematology.

[25]  H. Kantarjian,et al.  Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options , 1996 .

[26]  P. Ljungman,et al.  Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. , 1995, Bone marrow transplantation.

[27]  M. Hessner,et al.  Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. , 1995, Blood.

[28]  J. Goldman,et al.  Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. , 1995, Blood.

[29]  K. Sullivan,et al.  Unrelated donor marrow transplantation in children. , 1995, Blood.

[30]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[31]  G. Longton,et al.  The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. , 1995, Blood.

[32]  G. Dini,et al.  Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. , 1995, Blood.

[33]  A. Elmaagacli,et al.  Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. , 1995, Blood.

[34]  D. Blaise,et al.  Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). , 1995, Blood.

[35]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.

[36]  V. Vitale,et al.  Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). , 1993, Bone marrow transplantation.

[37]  N. Ramsay,et al.  Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Kersey,et al.  RISK FACTORS FOR ACUTE GRAFT‐VERSUS‐HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION , 1991, Transplantation.

[39]  A. J. Altman,et al.  Chronic leukemias of childhood. , 1988, Pediatric clinics of North America.

[40]  K B McCredie,et al.  Characteristics of accelerated disease in chronic myelogenous leukemia , 1988, Cancer.

[41]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukemia. , 1986, The New England journal of medicine.

[42]  A. Rimm,et al.  ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA , 1984, The Lancet.

[43]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[44]  K. Sullivan,et al.  Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. , 1998, Blood.

[45]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Lancet.

[46]  H. Kantarjian,et al.  Treatment of myelogenous leukemia: current status and investigational options. , 1996, Blood.

[47]  M. Horowitz,et al.  Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.

[48]  D. Weisdorf,et al.  Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. , 1994, Bone marrow transplantation.

[49]  M. Horowitz,et al.  Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. , 1993, Blood.

[50]  F. Oski,et al.  Hematology of Infancy and Childhood , 1974 .